CD44 and hepatocellular carcinoma: [202], JAK/STAT activation has been identified as a crucial part of inducing SP and CD44+ tumorigenic cells in hepatocellular carcinoma; using JAK/STAT inhibitors (TG101209 and AZ960) could effectively induce apoptosis in hepatic CSCs as well as delay tumor formation.